Injection site reactions , if present, typically resolve within days of the last injection
Currently, an ongoing phase III, multicenter, randomized, sham-controlled, double-blind trial is evaluating AT-04s efficacy and safety for endometriosis-related pain (dysmenorrhea, dyspareunia, chronic pelvic pain), with the primary outcome being the change in Numeric Rating Scale score at 16 weeks ( 4.5 Disease heterogeneity and subtype-specific therapeutic strategies Endometriosis exhibits significant clinical and biological heterogeneity, encompassing diverse anatomical subtypessuperficial peritoneal endometriosis (SPE), ovarian endometriomas (OMA), and deep infiltrating endometriosis (DIE)each with distinct pathophysiological features, symptom profiles, and fertility implications ( Table 1 )
Imbard A, Benoist JF, Esse R, Gupta S, Lebon S, de Vriese AS, et al
Remove patch and discard